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Abstract
Introduction: Introduced in the early 1960s, diazepam remains among the most frequently prescribed
benzodiazepine-type sedatives and hypnotics. Patients with chronic use of short-acting benzodiazepines are
frequently switched to diazepam because the accumulating, long-acting metabolite, N-desmethyl-diazepam,
prevents benzodiazepine-associated withdrawal symptoms, which can occur during trough plasma levels of short-
acting benzodiazepines. Although mild to moderate withdrawal symptoms are frequently observed during
benzodiazepine switching to diazepam, severe medical complications associated with this treatment approach
have thus far not been reported.
Case presentation: A 64-year-old female Caucasian with major depression, alcohol dependence and
benzodiazepine dependence was successfully treated for depression and, after lorazepam-assisted alcohol
detoxification, was switched from lorazepam to diazepam to facilitate benzodiazepine discontinuation. Subsequent
to the benzodiazepine switch, our patient unexpectedly developed an acute delirious state, which quickly remitted
after re-administration of lorazepam. A newly diagnosed early form of mixed dementia, combining both vascular
and Alzheimer-type lesions, was found as a likely contributing factor for the observed vulnerability to
benzodiazepine-induced withdrawal symptoms.
Conclusion: Chronic use of benzodiazepines is common in the elderly and a switch to diazepam often precedes
benzodiazepine discontinuation trials. However, contrary to common clinical practice, benzodiazepine switching to
diazepam may require cross-titration with slow tapering of the first benzodiazepine to allow for the build-up of N-
desmethyl-diazepam, in order to safely prevent severe withdrawal symptoms. Alternatively, long-term treatment
with low doses of benzodiazepines may be considered, especially in elderly patients with chronic use of
benzodiazepines and proven vulnerability to benzodiazepine-associated withdrawal symptoms.
Introduction
The benzodiazepine (BZD)-type sedatives and hypnotics,
introduced in the 1960s, marked a major advance in the
treatment of anxiety, depression, insomnia and seizures,
not least because of their improved therapeutic index.
The first BZDs marketed by F. Hoffmann-La Roche,
chlordiazepoxide (Librium®) and diazepam (Valium®),
became immensely popular. Diazepam was the most
widely prescribed drug in the United States and Europe
for nearly two decades. Even with the subsequent intro-
duction of numerous other BZDs, diazepam remained
one of the first-choice BZDs among prescribers and in
1985 was added to the World Health Organization’s
essential medicines list [1] for its anti-convulsant, anxioly-
tic, sedative-hypnotic and pre-medicant uses. In 2009,
lorazepam was added to this list and is now recom-
mended as an alternative to diazepam, notably for its
anti-convulsant properties. The superior efficacy of lora-
zepam over diazepam in the treatment of status epilepti-
cus, as demonstrated by Alldredge et al. nearly one
decade ago [2], is explained, at least in part, by the phar-
macokinetic properties of both drugs, which were
described in detail in the 1980s by Greenblatt et al. [3,4].
BZD-associated withdrawal symptoms have been
recognized for as long as BZDs have been in use. Over
the years, it has become abundantly clear that chronic
use of BZDs results in tolerance, rebound phenomena
and dependence, making it difficult for patients to
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discontinue BZD use. The two basic treatment options
available to patients with chronic BZD use are (i) BZD
discontinuation or (ii) low-dose BZD maintenance.
Where BZD discontinuation is favored, a frequently
employed BZD detoxification strategy is to switch to
diazepam, or to other BZDs with long elimination half-
lives of the parent drug or its active metabolites,
followed by slow tapering of the drug. In individuals
with chronic BZD use, a BZD switch to diazepam [5]
frequently results in mild or moderate withdrawal symp-
toms, such as distortions in perception, mood and cog-
nition or disturbances in sensory and motor functions.
However, severe medical complications, such as seizures
or delirium, which are known to occur relatively infre-
quently, even after abrupt BZD discontinuation, have
not been associated with a transfer to diazepam. In par-
ticular, withdrawal-induced delirium associated with a
switch from lorazepam to diazepam has thus far not
been reported. Interestingly, however, Onyett pointed
out as early as 1989 that, in some cases, switching
patients from lorazepam to diazepam may require cross-
titration [6]. Perhaps the only report describing a similar
case was published by Zipursky et al. [7]. The authors
described a 68-year-old patient with alprazolam withdra-
wal delirium unresponsive to treatment with diazepam
but responsive to treatment with alprazolam [7].
In this report we describe the case of an elderly
woman with a number of mental and physical condi-
tions who developed an acute delirious state after being
switched from lorazepam to diazepam. Drug pharmaco-
kinetics and psychiatric vulnerabilities are considered as
possible causal factors.
Case presentation
A 64-year-old Caucasian woman with major depression
(Diagnostic and Statistical Manual of Mental Disorders-
Text Revision (DSM IV-TR): 296.33), alcohol depen-
dence (DSM IV-TR: 303.90) and benzodiazepine (loraze-
pam) dependence (DSM IV-TR: 304.10) was referred to
a specialist ward for the treatment of substance use and
co-occurring mental disorders. Daily use of alcohol
started ten years prior to admission and daily use of lor-
azepam one year prior. In addition, our patient had a
history of medical conditions for which she had been
receiving medication. Levothyroxine was used to treat
hypothyroidism (thyroxine-stimulating hormone < 0.01
mU/L; free thyroxine = 20.9 pmol/L, free tri-iodothyro-
nine = 8.5 pmol/L), standard female hormone replace-
ment therapy consisting of 1 mg 17b-estradiol and 5 mg
dydrogesterone was used to alleviate and prevent symp-
toms associated with menopause, and atorvastatin was
prescribed to control hyperlipidemia. Felodipine, meto-
prolol and lisinopril were used to treat hypertension.
Salicylate was used for the prevention of cardiac
infarction. Pantoprazole was used to alleviate symptoms
related to gastro-esophageal reflux. All prescriptions,
including a previous trial with the antidepressant mian-
serin, were well tolerated without significant side effects
and, except for mianserin, were continued after admis-
sion without dose changes.
On admission, lorazepam, at 5-10 mg daily, was begun
to prevent alcohol- and BZD-associated withdrawal
symptoms. Antidepressant treatment with mianserin
(60 mg daily) resulted in a partial response. A three-
week add-on trial with venlafaxine (maximum dose 450
mg daily) resulted in further improvement of depressive
symptoms. However, residual depressive symptoms
persisted and mianserin was switched to mirtazapine
(maximum dose 75 mg daily). Complete remission was
achieved two months later and venlafaxine maintained
at 150 mg daily and mirtazapine at 60 mg daily (relapse
prevention).
Lorazepam was tapered and discontinued after six
weeks of treatment. One day after the last lorazepam
dose, our patient exhibited difficulties in maintaining
attention and showed signs of psychomotor agitation,
anxiety and disturbed thought processes, such as loo-
sened, illogical and tangential associations. Dissociative
symptoms were also observed. These signs were consis-
tent with an ensuing BZD withdrawal syndrome (DSM
IV-TR: 292.0) and suggested that an even more pro-
tracted discontinuation phase may have been necessary.
Delirium was not diagnosed at this time because orien-
tation remained intact and the severity of the symptoms
was not in excess of those usually associated with a
BZD withdrawal syndrome. Lorazepam was resumed at
3 mg per day. Symptoms of withdrawal resolved and
lorazepam was maintained at 3 mg daily for one month.
Lorazepam was then discontinued without tapering, and
diazepam was started at an equivalent dose of 15 mg
daily. Less than one day after the BZD switch, our
patient became increasingly irritable and agitated and
eventually exhibited fluctuating levels of consciousness
with reduced clarity of awareness and reduced ability to
maintain attention. Disorientation, incomprehensible
speech and memory deficits were also noted. The diag-
nosis of a BZD intoxication delirium was ruled out
based on the absence of slurred speech, incoordination,
unsteady gait, nystagmus or stupor. Our patient was
diagnosed with BZD withdrawal delirium (DSM IV-TR:
292.81) and received 4 mg of lorazepam combined with
4 mg of haloperidol. The acute delirious state resolved
within hours and our patient remained well. Haloperidol
was stopped after two weeks. Lorazepam was continued
at 4 mg daily. Our patient was dismissed one month later
with a lorazepam maintenance dose of 4 mg per day.
An initial review of the prescriptions and the diagnos-
tic tests performed in the course of treatment failed to
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reveal our patient’s vulnerabilities to delirious states.
Except for a slight increase of plasma diazepam levels in
the presence of metoprolol, no relevant drug interac-
tions were identified. A physical examination, laboratory
workup and an analysis of cerebrospinal fluid were
unremarkable. In particular, there was no evidence of
hepatic dysfunction. Serum levels of alanine and aspar-
tate aminotransferase, alkaline phosphatase, lactate
dehydrogenase, and bilirubin were normal. Prothrombin
time was within the normal range. Serum g-glutamyl-
transferase was slightly elevated (74 U/L; normal range,
< 55 U/L). However, serum concentrations of O-des-
methyl-venlafaxine (a liver-derived metabolite of venla-
faxine) were seven-fold higher than those of venlafaxine.
Taken together, these results suggested normal liver
function with intact hepatic drug metabolism and ruled
out the differential diagnosis of a diazepam-exacerbated
hepatic encephalopathy.
Electroencephalogram recordings showed the rhythm
of alpha waves (11-12 Hz) and beta waves (18-22 Hz) to
be as expected during treatment with lorazepam. Epilep-
tiform discharges or focal abnormalities were not pre-
sent. Electrocardiogram recordings showed a normal
sinus rhythm with a frequency of around 90 per minute.
Neuropsychological tests revealed only mild cognitive
deficits. At the time these test were performed our
patient was receiving the medication to treat her physi-
cal conditions as described above. In addition, she
received mirtazapine (60 mg daily), venlafaxine (150 mg
daily) and lorazepam (4 mg daily). The Mini-Mental
State Examination score was 27. The Consortium to
Establish a Registry for Alzheimer’s Disease test revealed
minimal cognitive impairment, mainly affecting her ver-
bal memory (left hippocampus system), executive func-
tions (frontal lobe) and mental rotation (parietal lobe).
On the Hamburg Wechsler Intelligence test for adults,
she achieved 90 points, a score slightly below average.
Computed tomography scans showed no signs of brain
atrophy. However, using T2 pulses, magnetic resonance
imaging showed scattered sub-cortical signal distur-
bances in her frontal, parietal and occipital regions.
Additional signal disturbances were found in her pon-
tine regions and brain stem. Together, these findings
were consistent with sub-cortical atherosclerotic ence-
phalopathy, in other words, Binswanger’s disease. Posi-
tron emission tomography scanning of the brain using
the radio-labeled glucose analog 18F-fluorodeoxyglucose
(FDG) showed diminished FDG uptake in temporal and
parietal cortical regions. Lower FDG accumulation was
also found in parts of the visual cortex and in both her
basal ganglia and thalamus. The absence of hallucina-
tions, Parkinsonian or extra-pyramidal symptoms,
together with the previously well-tolerated trial with
haloperidol, argued against Lewy body dementia [8].
The most likely diagnosis was an early form of mixed
dementia, combining both vascular (DSM IV-TR:
290.40) and Alzheimer-type lesions (DSM IV-TR:
294.10). Thus, the neuro-imaging results suggested that
our patient might be liable to develop a delirious state
in response to chemically induced brain disturbances.
Before leaving our hospital, our patient was started on
donepezil, shown to improve cognition in Alzheimer’s
disease [9].
Discussion
In agreement with the present case, evidence now sug-
gests that (i) both short-and long-term BZD use is asso-
ciated with old age, female sex, psychological stress and
physical disease [10], (ii) long-term BZD use in old age
is typically associated with mood disorders, alcohol
abuse and female sex [11] and (iii) depression in old age
is associated with the use of alcohol and prescription
drugs, with female sex and with medical conditions such
as heart disease and Alzheimer’s disease [12].
Since chronic BZD use constitutes a risk for cognitive
decline [13] and since our patient was diagnosed with
an early form of dementia, exhibiting mild cognitive
impairments, the treatment goal was to discontinue
BZD use. However, since tapering lorazepam resulted in
unacceptable withdrawal symptoms, a switch to diaze-
pam was considered. At first glance, the observation
that switching lorazepam to an equivalent dose of diaze-
pam resulted in a withdrawal-induced delirious state is
puzzling because BZD withdrawal delirium is usually
associated with sudden discontinuation from short-act-
ing BZDs [14], and long-acting BZDs or long-acting
BZD metabolites are usually associated with intoxica-
tion-induced but not withdrawal-induced delirium [14].
Generally, however, long-acting BZDs, particularly at
high doses, are frequently associated with delirium and
commonly contribute to cognitive impairment in
dementia [14]. An interesting explanation is offered by
Greenblatt et al. who found that, despite its longer half-
life, unbound diazepam distributes more extensively into
tissue than lorazepam does [3] and thus has a shorter
duration of action than lorazepam. Additionally, as
shown in animals, diazepam brain-to-plasma ratios
decrease rapidly within minutes [4]. Lorazepam, in con-
trast, shows a more sustained build-up in the central
nervous system [4]. Consequently, switching from lora-
zepam to diazepam may lead to withdrawal symptoms
even when equivalent doses are used.
While our case demonstrates a particular vulnerability
to BZD-induced withdrawal symptoms in a patient with
discrete vascular and Alzheimer-type lesions, the mole-
cular mechanisms responsible for this vulnerability
remain unexplained. However, irrespective of the pre-
sence of vascular or Alzheimer-type lesions, which may
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be associated with such vulnerability, the complex nat-
ure of the g-amino-butyric acid (GABA) system, through
which BZDs mediate their anxiolytic, sedative, anti-con-
vulsant and muscle relaxant effects, may provide other
clues.
GABA, the major inhibitory neurotransmitter in the
mammalian central nervous system, mediates fast post-
synaptic inhibition through binding to the GABA-A
receptor, a hetero-pentameric chloride-selective ligand-
gated ion channel [15]. To date, 19 different types of
GABA-A polypeptide chains (a1-a6, b1-b3, g1-g3, δ, ε,
θ, π, r1-r3) have been characterized [16]. Many of the
theoretically possible pentamers are not expressed at the
cell surface. Nevertheless, an impressive number of dif-
ferent GABA-A pentamers are found with different dis-
tributions in the mammalian brain. The most abundant
subtypes are 2a1-2b2-1g2, 2a2-2b3-1g2 and 2a3-2b3-
1g2 [16].
The observed vulnerability to BZD-induced withdra-
wal symptoms could be explained by the expression pat-
terns of GABA-A pentamers in our patient ’s brain,
because different BZD effects are mediated by different
GABA-A pentamers [17]. Furthermore, the assumption
that the most extensively investigated prototypic agonist,
diazepam, exerts identical allosteric effects on GABA-A
receptors as other BZDs, lorazepam for example, may
not be true. These considerations leave open the possi-
bilities that inborn differences in the patient’s GABA
system, BZD-induced changes in this system [18] or
changes in the GABA system as a result of the assumed
mixed vascular and Alzheimer-type dementia may have
contributed to a special vulnerability to BZD-induced
withdrawal symptoms. Both clinical and basic research
is needed to support or dismiss these ideas as possible
mechanisms.
Conclusion
This case report describes a 64-year-old female Cauca-
sian with several pre-existing medical conditions and
psychiatric disorders common for her age. These were
treated successfully with one notable exception, BZD
dependence, for which discontinuation was the favored
treatment goal. Unexpectedly, our patient developed a
severe adverse reaction (delirium) associated with a
switch from lorazepam to diazepam.
Since BZD prescriptions in the elderly are common to
almost all medical subspecialties, severe adverse events
associated with BZD use must be reported quickly to
alert prescribers and to improve treatment safety and
quality. The present case suggests that elderly polymor-
bid patients with chronic BZD use may benefit from
cross-tapering when switched to diazepam. Finally, long-
term treatment with low doses of BZDs may be
considered in these patients when BZD discontinuation
trials fail.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Acknowledgements
Special thanks go to the health care professionals and laboratory technicians
who were involved in clinical diagnostics and laboratory testing. This work
was performed in accordance with the Declaration of Helsinki and with
Good Clinical Practice guidelines. No financial support, either from funding
agencies or from the pharmaceutical industry, was obtained.
Author’s information
The author is a board-certified psychiatrist and head of a private outpatient
facility for the treatment of substance use and co-occurring disorders. The
author has a background in molecular and cell biology research.
Competing interests
The author declares that they have no competing interests.
Received: 21 September 2010 Accepted: 26 May 2011
Published: 26 May 2011
References
1. Laing R, Waning B, Gray A, Ford N, ’t Hoen E: 25 years of the WHO
essential medicines lists: progress and challenges. Lancet 2003,
361(9370):1723-1729.
2. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, Gottwald MD,
O’Neil N, Neuhaus JM, Segal MR, Lowenstein DH: A comparison of
lorazepam and placebo for the treatment of out-of-hospital status
epilepticus. N Engl J Med 2001, 345(9):631-637, Erratum in N Engl J Med
2001 345(25):1860.
3. Greenblatt DJ, Divoll M: Diazepam versus lorazepam: relationship of drug
distribution to duration of clinical action. Adv Neurol 1983, 34:487-491.
4. Greenblatt DJ, Ehrenberg BL, Gunderman J, Scavone JM, Tai NT, Harmatz JS,
Shader RI: Kinetic and dynamic study of intravenous lorazepam:
comparison with intravenous diazepam. J Pharmacol Exp Ther 1989,
250(1):134-140.
5. Couvée JE, Zitman FG: The Benzodiazepine Withdrawal Symptom
Questionnaire: psychometric evaluation during a discontinuation
program in depressed chronic benzodiazepine users in general practice.
Addiction 2002, 97(3):337-345.
6. Onyett SR: The benzodiazepine withdrawal syndrome and its
management. J R Coll Gen Pract 1989, 39(321):160-163.
7. Zipursky RB, Baker RW, Zimmer B: Alprazolam withdrawal delirium
unresponsive to diazepam: case report. J Clin Psychiatry 1985,
46(8):344-345.
8. McKeith IG: Dementia with Lewy bodies. Br J Psychiatry 2002, 180:144-147.
9. Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer’s disease.
Cochrane Database Syst Rev 2006, 1:CD001190.
10. Zandstra SM, Furer JW, van de Lisdonk EH, Bor JH, Zitman FG, van Weel C:
Differences in health status between long-term and short-term
benzodiazepine users. Br J Gen Pract 2002, 52(483):805-808.
11. Petrovic M, Vandierendonck A, Mariman A, van Maele G, Afschrift M,
Pevernagie D: Personality traits and socio-epidemiological status of
hospitalised elderly benzodiazepine users. Int J Geriatr Psychiatry 2002,
17(8):733-738.
12. Mulsant BH, Ganguli M: Epidemiology and diagnosis of depression in late
life. J Clin Psychiatry 1999, 60(Suppl 20):9-15.
13. Paterniti S, Dufouil C, Alpérovitch A: Long-term benzodiazepine use and
cognitive decline in the elderly: the Epidemiology of Vascular Aging
Study. J Clin Psychopharmacol 2002, 22(3):285-293.
Bosshart Journal of Medical Case Reports 2011, 5:207
http://www.jmedicalcasereports.com/content/5/1/207
Page 4 of 5
14. Moore AR, O’Keeffe ST: Drug-induced cognitive impairment in the elderly.
Drugs Aging 1999, 15(1):15-28.
15. Jacob TC, Moss SJ, Jurd R: GABAA receptor trafficking and its role in the
dynamic modulation of neuronal inhibition. Nat Rev Neurosci 2008,
9(5):331-343.
16. Wafford KA: GABAA receptor subtypes: any clues to the mechanism of
benzodiazepine dependence? Curr Opin Pharmacol 2005, 5(1):47-52.
17. Rudolph U, Mohler H: GABA-based therapeutic approaches: GABAA
receptor subtype functions. Curr Opin Pharmacol 2006, 6(1):18-23.
18. Lilly SM, Zeng XJ, Tietz EI: Role of protein kinase A in GABAA receptor
dysfunction in CA1 pyramidal cells following chronic benzodiazepine
treatment. J Neurochem 2003, 85(4):988-998.
doi:10.1186/1752-1947-5-207
Cite this article as: Bosshart: Withdrawal-induced delirium associated
with a benzodiazepine switch: a case report. Journal of Medical Case
Reports 2011 5:207.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bosshart Journal of Medical Case Reports 2011, 5:207
http://www.jmedicalcasereports.com/content/5/1/207
Page 5 of 5
